Cardiac Metabolism as a Therapeutic Target

Abstract

Cardiac metabolism plays a central role in myocardial energy production and function. Dysregulation of cardiac metabolic pathways is implicated in the pathogenesis and progression of various cardiovascular diseases, including heart failure, ischemic heart disease, and cardiomyopathies. Recent advances in understanding the metabolic adaptations and maladaptations of the heart have highlighted new therapeutic opportunities. This review explores the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic modalities, and current as well as emerging therapies targeting cardiac metabolism. Emphasis is placed on mechanistic insights, translational research, and guideline-directed interventions relevant for clinicians and healthcare professionals.

Introduction

The myocardium requires a continuous and substantial supply of energy, predominantly in the form of adenosine triphosphate (ATP), to sustain contractile function, ionic homeostasis, and cellular integrity. Cardiac metabolism involves a dynamic interplay between substrates such as fatty acids, glucose, lactate, amino acids, and ketone bodies. In pathologic states, the heart undergoes metabolic remodeling, which can either be adaptive or maladaptive, influencing disease progression and therapeutic response. The targeting of cardiac metabolic pathways is gaining traction as a novel approach to improve outcomes in patients with cardiovascular disease, offering additional strategies beyond conventional hemodynamic modulation.

Epidemiology / Disease Burden

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for an estimated 17.9 million deaths annually. Heart failure (HF), ischemic heart disease (IHD), and diabetic cardiomyopathy are among the primary clinical entities wherein metabolic dysregulation plays a pivotal role. The prevalence of HF alone is projected to rise with the aging population and increasing prevalence of metabolic risk factors, including obesity and diabetes mellitus. Epidemiological studies underscore the significance of metabolic remodeling in both acute and chronic cardiac conditions, highlighting the unmet need for metabolic-centric therapeutic strategies.

Pathophysiology

Under physiologic conditions, the adult heart derives 60-90% of its ATP from fatty acid oxidation and the remainder from glucose oxidation, lactate, and other substrates. Pathological stressors, such as ischemia, pressure overload, or neurohormonal activation, induce a shift in substrate utilization. During ischemia, the heart increases its reliance on glucose due to its greater oxygen efficiency, but chronic metabolic remodeling can lead to mitochondrial dysfunction, increased reactive oxygen species (ROS), and impaired ATP generation. In heart failure, there is a reversion to a fetal metabolic phenotype characterized by reduced fatty acid oxidation, increased glycolysis, and diminished metabolic flexibility. These maladaptations contribute to contractile dysfunction, arrhythmogenesis, and disease progression.

Risk Factors

Multiple risk factors contribute to the development of cardiac metabolic disturbances. These include diabetes mellitus, metabolic syndrome, obesity, hypertension, sedentary lifestyle, and genetic predispositions affecting metabolic enzymes and transporters. Hyperglycemia and insulin resistance promote deleterious metabolic shifts, favoring lipotoxicity, glucotoxicity, and oxidative stress. Additionally, aging and chronic inflammation further exacerbate metabolic inefficiency, predisposing to adverse cardiac remodeling and functional decline.

Clinical Features

Metabolic dysregulation in the heart manifests clinically as impaired exercise tolerance, fatigue, and progressive symptoms of heart failure, such as dyspnea, peripheral edema, and orthopnea. In ischemic heart disease, metabolic inflexibility may contribute to myocardial stunning, hibernation, and arrhythmias. In diabetic cardiomyopathy, early diastolic dysfunction often precedes overt systolic impairment, reflecting subclinical metabolic derangements. Advanced imaging and biomarker profiling can reveal alterations in substrate utilization, energy reserve, and mitochondrial function before the onset of structural changes.

Diagnosis

Diagnostic assessment of cardiac metabolism integrates non-invasive imaging modalities, circulating biomarkers, and invasive metabolic studies. Positron emission tomography (PET) with radiolabeled substrates (e.g., 18F-FDG, 11C-palmitate) enables quantification of myocardial glucose and fatty acid uptake. Magnetic resonance spectroscopy (MRS) allows measurement of myocardial phosphocreatine-to-ATP ratios, reflecting energetic status. Biomarkers such as B-type natriuretic peptide (BNP), troponins, and metabolic intermediates can provide indirect evidence of metabolic stress. Recent advances in metabolomics and proteomics are expanding the diagnostic toolkit for clinical and research applications.

Treatment & Management

Therapeutic targeting of cardiac metabolism encompasses both pharmacologic and non-pharmacologic strategies. Conventional heart failure therapies, such as beta-blockers, ACE inhibitors, and mineralocorticoid receptor antagonists, indirectly modulate myocardial metabolism by reducing neurohormonal activation and wall stress. Direct metabolic modulators include trimetazidine, ranolazine, and perhexiline, which shift substrate utilization from fatty acids to glucose, improving oxygen efficiency and contractile function. Nutritional interventions, exercise training, and weight management further enhance metabolic flexibility and energy efficiency. Patient selection, monitoring, and individualized therapy remain essential for optimizing clinical outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel metabolic therapies targeting specific enzymatic and regulatory pathways. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed for diabetes, have demonstrated significant reductions in heart failure hospitalizations and cardiovascular mortality, likely through favorable effects on myocardial energetics, ketone utilization, and diuresis. Agents modulating pyruvate dehydrogenase (PDH) activity, mitochondrial biogenesis, and peroxisome proliferator-activated receptors (PPARs) are under investigation. Gene therapy and RNA-based interventions targeting metabolic regulators offer potential for disease modification. Ongoing clinical trials are evaluating the safety and efficacy of these approaches in various patient populations.

Guideline Recommendations

International guidelines for heart failure and ischemic heart disease emphasize the optimization of guideline-directed medical therapy (GDMT) with beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid antagonists, and SGLT2 inhibitors. Recent updates from the European Society of Cardiology (ESC) and American Heart Association (AHA) incorporate SGLT2 inhibitors as foundational therapy for heart failure with reduced ejection fraction, regardless of diabetes status. While specific recommendations for direct metabolic modulators are limited, their use is considered in selected patients with chronic angina or heart failure refractory to standard therapy. Multidisciplinary care, risk factor modification, and patient education remain integral components of comprehensive management.

Conclusion

Targeting cardiac metabolism represents a promising and rapidly evolving therapeutic paradigm in cardiovascular medicine. Mechanism-based interventions have the potential to improve myocardial efficiency, attenuate disease progression, and enhance quality of life for patients with heart failure, ischemic heart disease, and metabolic cardiomyopathies. Ongoing research will further elucidate optimal strategies for patient selection, treatment individualization, and long-term outcomes. Integration of metabolic therapies into clinical practice requires a nuanced understanding of pathophysiology, guideline recommendations, and emerging evidence to maximize patient benefit.